Catechol-O-methyl transferase Val158Met gene ... - CiteSeerX

6 downloads 67 Views 290KB Size Report
Jan 25, 2005 - University of Iowa, 200 Hawkins Drive, Iowa City, IA 52252, USA. E-mail: beng-ho@uiowa. ... dizygotic twin pairs. Greater familial .... Regional cerebral blood flow (rCBF) was measured using the bolus ... transit, determined by time–activity curves from a ..... Springs, CO, March 28–April 2, 2003. References.
Molecular Psychiatry (2005) 10, 287–298 & 2005 Nature Publishing Group All rights reserved 1359-4184/05 $30.00 www.nature.com/mp

ORIGINAL RESEARCH ARTICLE

Catechol-O-methyl transferase Val158Met gene polymorphism in schizophrenia: working memory, frontal lobe MRI morphology and frontal cerebral blood flow B-C Ho1, TH Wassink1, DS O’Leary1, VC Sheffield2 and NC Andreasen1,3,4 1

Department of Psychiatry, Roy J and Lucille A Carver College of Medicine, University of Iowa, Iowa City, IA, USA; Department of Pediatrics, Division of Molecular Genetics, Howard Hughes Medical Institute, University of Iowa, Iowa City, IA, USA; 3The MIND Institute, Albuquerque, NM, USA; 4Department of Psychiatry, University of New Mexico, Albuquerque, NM, USA 2

The catechol-O-methyl transferase (COMT) gene is considered a leading schizophrenia candidate gene. Although its role in increasing schizophrenia susceptibility has been conflicting, recent studies suggest the valine allele may contribute to poor cognitive function in schizophrenia. V158M COMT genotype was obtained on 159 schizophrenia patients and 84 healthy controls. The effects of COMT genotype on four measures of working memory/ executive functions (Wisconsin Card Sorting, digit span backward, Trail Making and N-back tests) and on MRI frontal brain volumes were examined. Genotype distributions were not significantly different between patients and controls. There were no significant genotype or genotype-by-group effects on any working memory/executive function measures. No genotype or genotype-by-diagnosis interaction effects were found with MRI frontal lobe volumes. Randomization analyses using [15O]H2O positron emission tomography (PET) cerebral blood flow data found Val/Val patients had higher frontal lobe activation than Met/Met patients while performing the one-back task. Overall, these findings do not support a major role for COMT in increasing susceptibility for schizophrenia or in mediating frontal lobe function. Age-related changes and phenotypic heterogeneity of schizophrenia may influence the complex relationships between COMT genotype and cognition. Molecular Psychiatry (2005) 10, 287–298. doi:10.1038/sj.mp.4001616 Published online 25 January 2005 Keywords: endophenotype; dopamine; MRI; candidate gene; association study; PET

Schizophrenia is a severe and disabling neuropsychiatric disorder. Although a century of genetic epidemiological research has provided strong evidence for a genetic basis, success in the search for schizophrenia susceptibility genes has thus far been limited. Risks for developing schizophrenia appear to be related to complex interactions between multiple genes, and between genes and environmental factors. The phenotype of schizophrenia is equally complex, and encompasses deficits in multiple domains of brain function, thereby presenting an elusive and difficult target for research into the neurobiological and genetic underpinnings of schizophrenia.1,2 One strategy to address the challenges from genetic complexity and phenotypic heterogeneity has been to study endophenotypes.3,4 Endophenotypes can be neurocognitive, neurophysiological, biochemical or neuroanatomical traits that correlate with the disease and/or disease severity.5 These traits are heritable and can be measured in unaffected relatives. Studying endophenoCorrespondence: Dr B-C Ho, Department of Psychiatry 2880 JPP, University of Iowa, 200 Hawkins Drive, Iowa City, IA 52252, USA. E-mail: [email protected] Received 18 May 2004; revised 9 August 2004; accepted 4 October 2004

types (vs using psychiatric diagnostic categories) may potentially provide more power for genetic studies.6,7 Endophenotypes are presumably biologically closer to the gene, transmitted in a less complex manner and can be more accurately assessed. Using such an approach, investigations into putative endophenotypes, such as smooth-pursuit eye movements and prepulse inhibition, have already identified potential schizophrenia susceptibility genetic loci and candidate genes.8–11 Working memory is widely considered to be an endophenotype for schizophrenia. Working memory refers to the neuropsychological construct of ‘temporary storage and manipulation of the information necessary for such complex cognitive tasks as language comprehension, learning and reasoning’.12 Schizophrenia patients as well as their unaffected relatives perform poorly on tasks that assess working memory function.13–23 Working memory is moderately heritable with 43–49% of its variability accounted by genetic factors24 In a series of studies involving a population isolate, a significant additive genetic heritability estimate was found in verbal working memory, and for visual working memory at a trend level.20,21,25 Spatial working memory performance was more highly correlated in monozygotic twins than in

COMT and frontal lobe functions and morphology in schizophrenia B-C Ho et al

288

dizygotic twin pairs. Greater familial loading was associated with greater impairment in working memory performance. Working memory also appears to be a stable trait. Deficits have been demonstrated throughout the course of schizophrenia,26,27 in neuroleptic-naı¨ve, medicated and unmedicated patients, and are relatively unaffected by antipsychotic treatment.16,28–30 Dopamine neurotransmission in the dorsolateral prefrontal cortex (DLPFC) plays a pivotal role in working memory. Single unit recording studies in non-human primates as well as functional neuroimaging studies in humans have consistently demonstrated this relationship.31,32 The mesocortical dopamine system, which ascends from the ventral tegmental area, provides extensive connections to the neocortex,33,34 where D1 receptors are the most highly expressed of the dopamine receptors.35,36 In nonhuman primates studied using delayed response paradigms, stimulation of D1 receptors in the DLPFC enhances working memory.37,38 These observations, together with the association between working memory deficits and aberrant DLPFC activation in schizophrenia patients, provide convergent evidence that disruptions in DLPFC dopamine neurotransmission may underlie working memory deficits in schizophrenia.29,39–43 Elimination of extracellular dopamine relies on synaptic reuptake (via dopamine transporter and norepinephrine transporter) as well degradation by monoamine oxidase and catechol-O-methyl transferase (COMT).44–47 Owing to its role in the catabolism of dopamine, the COMT gene has been extensively studied as a schizophrenia candidate gene. In humans, there is a common V158M functional polymorphism48 where a methionine (Met) substituted for a valine (Val) leads to a four-fold reduction in COMT enzyme activity.49 Furthermore, the COMT gene is localized to chromosome 22q11, a region which has been implicated in schizophrenia linkage studies.50 Deletion of chromosome 22q11 (as seen in velocardiofacial syndrome) is associated with high rates of schizophrenia-like psychosis.51 A recent study has generated renewed interest in this gene, especially with regard to its role in mediating working memory and cognition.52 The association between low-activity Met allele and better cognitive performance may be related to increased prefrontal dopamine bioavailability.52,53 However, even though the COMT gene is

Table 1

Materials and methods Subjects In all, 159 schizophrenia patients and 84 healthy volunteers were obtained through the University of Iowa Mental Health Clinical Research Center (MHCRC). These subjects have participated in various MHCRC research studies approved by the University of Iowa institution review board. All subjects gave written informed consent to undergo research assessments. Patients were evaluated using a semistructured interview instrument, Comprehensive Assessment of Symptoms and History (CASH),64 from which schizophrenia diagnoses meeting DSM-III-R or DSM-IV criteria were based. Healthy volunteers were recruited from the community through newspaper advertisements. They were initially screened by telephone, and further evaluated using an abbreviated version of the CASH to exclude subjects with current or past medical, neurological or psychiatric illnesses. To minimize the likelihood of spurious association arising from ethnic stratification, only subjects of Caucasian ancestry were included into this report. Sociodemographic characteristics of the sample are summarized in Table 1. Both groups were of comparable age. A significantly greater proportion of patients were male. Patients also had fewer years of education

Sociodemographics of the sample

Controls N (% males) Age (years) Education (years) Full scale IQ Parental education (years)

Molecular Psychiatry

an appealing candidate gene in schizophrenia, case– control as well as family-based association studies to date have had mixed findings with regard to its contribution to schizophrenia susceptibility.52,54–63 The aim of this study is to examine the role of V158M COMT polymorphism in working memory in schizophrenia. This study integrates data from multimodal investigational approaches, including neuropsychology, molecular genetics, morphometric and functional neuroimaging, to probe the genetic and phenotypic complexities of schizophrenia. This study extends the growing literature on COMT by examining several concurrent measures of working memory/ executive function in a sample of recent-onset schizophrenia patients (as compared to the more chronically ill patients examined in previous studies). In addition, no prior studies have examined the relationships between V158M COMT genotype and MRI frontal lobe morphology, nor have they compared prefrontal cerebral blood flow between schizophrenia patients with different COMT genotypes.

84 27.0 14.8 109 13.6

(40.48) (7.03) (1.55) (12.05) (2.18)

Patients 159 26.5 12.9 91.0 13.7

(74.21) (7.35) (1.94) (12.45) (2.63)

Statistic

P-value

w2 ¼ 26.7 t241 ¼ 0.53 t241 ¼ 8.51 t241 ¼ 11.01 t241 ¼ 0.49

o0.001 0.60 o0.0001 o0.0001 0.63

COMT and frontal lobe functions and morphology in schizophrenia B-C Ho et al

and lower full scale IQ. However, parental educational attainment was comparable between the groups. Patients were evaluated relatively early in the course of their illness. The mean duration of illness (since the onset of first psychiatric hospitalization) was 2.5 years (SD ¼ 4.73). A total of 79 patients (48%) were evaluated during their first psychiatric hospitalization, and 57 (35%) were neuroleptic naı¨ve. The median duration of lifetime neuroleptic treatment was 2 months (25th and 75th interquartile range ¼ 12 months). Genetic analyses DNA was prepared by high-salt extraction from whole blood.65 The COMT codon 108/158 polymorphism was determined by restriction fragment length polymorphism analysis. PCR amplification was performed on a 165 bp fragment of the COMT gene using the primers 50 -GGGCCTACTGTGGCTACTCA-30 (forward) and 50 -GGCCCTTTTTCCAGGTCTGACA-30 (backward). Each 20 ml PCR reaction contained 20 ng genomic DNA, 5.0 pM of each primer, 400 mM of each dNTP, 0.1 U of Taq DNA polymerase, 2.0 ml PCR buffer (100 mM Tris-HCl (pH 8.8), 500 mM KCl, 15 mM MgCl2, 0.01% gelatin (w/v)), 4.0 ml betaine and 10.5 ml water. Cycling conditions were as follows: initial denaturation was at 941C for 3 min, followed by 40 temperature cycles consisting of 30 s at 941C for denaturation, 30 s at 601C for annealing and 30 s at 721C for extension, followed by a final elongation at 721C for 5 min. The PCR products were then digested by restriction enzyme NlaIII at 371C for 3 h. Digestion products were electrophoresed on 4% NuSieve agarose gel, and visualized by ethidium bromide staining under ultraviolet light. Genotyping was performed blind to subject’s clinical status. Working memory/executive function assessment Although working memory performance has been widely studied, there remains considerable debate with regard to its definition and how to best quantify the construct.66 Some investigations emphasize the temporary storage component of working memory, while others stress the importance of measuring the executive function component of working memory (ie both holding information ‘online’ as well as manipulation of stored information). Until a better consensus has been reached with regard to its definition and measurement, working memory performance may be best assessed by using a combination of different tests.66,67 In this study, working memory assessment consists of a battery of four tests: Wisconsin Card Sorting Test (WCST),68 WAIS-R digit span backward, Trail Making test and N-back test. The first three working memory tests are part of a standard neuropsychological test battery, while the N-back test was administered during a positron emission tomography (PET) study on a subset of the sample (see below). WCST raw test scores for the number of perseverative errors were normalized for age and educational attainment, and

transformed to t-scores based on population norms68 (population mean ¼ 50, SD ¼ 10, higher scores indicate better performance). The WAIS-R digit span subtest typically combines forward and backward performance into a single score. In this study, only the total raw score of the number of correct items from the backward portion of the test is used, since previous studies suggest that the backward span task is a more robust measure of working memory.17,66 The Trail Making test is a measure of executive functioning and set alternation.69 Trail A involves connecting numbers in succession, while Trail B requires subjects to connect numbers and letters alternately in successive order. Working memory load in the Trail Making test consists of keeping the next target in mind while searching for the target on the sheet. By subtracting Trail A from Trail B, it is possible to assess frontal lobe functions by eliminating motor speed.70 The time difference (s) taken to connect all items correctly on Trails A and B is used in the analysis.

289

MRI acquisition and image processing Images were obtained on a 1.5-T GE Signa MR scanner. Three different MR sequences were acquired for each subject (ie T1-weighted spoiled grass, proton density (PD) and T2-weighted images). The imaging parameters have been described previously.71 The images were processed using the locally developed BRAINS (Brain Research: Analysis of Images, Networks, and Systems) software package. Detailed descriptions of image analysis methods have been provided elsewhere.71–74 In brief, the T1-weighted images were spatially normalized and resampled so that the anterior–posterior axis of the brain was realigned parallel to the anterior–posterior commissure line, and the interhemispheric fissure was aligned on the other two axes. The T2- and PDweighted images were aligned to the spatially normalized T1-weighted image using an automated image registration program.75 These images were then subjected to a linear transformation into standardized stereotaxic Talairach atlas space76 to generate automated measurements of frontal, temporal, parietal, and occipital lobes, cerebellum, and subcortical regions.77 To further classify tissue volumes into gray matter (GM), white matter (WM) and cerebrospinal fluid (CSF), we employed a discriminant analysis method of tissue segmentation based on automated training class selection that utilized data from the T1, T2 and PD sequences.78 In this study, we examined frontal lobe GM, WM and CSF volumes. PET data acquisition and image processing During image acquisition, subjects lay reclined and are oriented in the PET scanner with laser light guides aligned at the orbital meatal line of the brain. Stimuli for the one-back task were presented on a video monitor. The baseline condition consisted of a checkerboard flashing at a rate of 0.5 Hz for 40 s. Subjects were told to fixate on a dot at the center of the checkerboard. During the one-back condition, the Molecular Psychiatry

COMT and frontal lobe functions and morphology in schizophrenia B-C Ho et al

290

same 0.5 Hz flashing checkerboard stimulus was presented but each checkerboard had an asterisk. The location of the asterisk changed with each flash. The subject was instructed to press the index finger button if he/she saw the asterisk appear in the same location on two consecutive flashes. Although subjects were told that this may happen more than once, only one set of two consecutive flashes were presented 35 s into the stimulus. Reaction time (ms) in this one-back task was used for analysis. Regional cerebral blood flow (rCBF) was measured using the bolus [15O]H2O method79 with a GE4096PLUS Scanner. A total of 15 slices (6.5 mm center-tocenter) were acquired with a 10-cm axial field of view. Images were acquired over a 100-s interval following venous injection of 50–75 mCi of [15O]H2O. Images were reconstructed for a 40-s interval following bolus transit, determined by time–activity curves from a region-of-interest over a cerebral artery.80 Arterial blood sampling allowed calculation of tissue perfusion in ml/min/100 g tissue using the autoradiographic method.80 The outlines of the PET images were automatically identified with an edge detection algorithm and the PET images for each condition for each subject were coregistered with their MR images using a variance minimization program.75 An 18 mm Hanning filter was applied to the PET images for each condition to eliminate residual anatomical variability. The PET study was carried in 17 healthy volunteers and 16 schizophrenia patients to examine rCBF differences during working memory performance. Among the 17 healthy controls, two subjects had Met/Met genotype, 12 Met/Val and three Val/Val. Of the 16 schizophrenia patients, seven had Met/Met genotype, three Met/Val and six Val/Val. Owing to this genotype distribution, only the seven Met/Met and six Val/Val patients were used in subsequent PET analyses. Statistical analyses COMT genotype frequencies were compared between subjects and controls using w2 tests. Analyses of the relationships between COMT genotype and the three measures of working memory/executive function (ie WCST, WAIS-R digit span backward and Trail Making test) and with MRI frontal lobe volumes (GM, WM and CSF) were performed using ANOVAs. In each general linear model, the respective trait measure was entered as the dependent measure with genotype and affectation status as independent variables. Intracranial volume and age were entered as covariates in the MRI frontal lobe morphology analyses. For the [15O]H2O PET data, a nonparametric randomization analysis81 was performed to compare the rCBF response of seven Met/Met patients and six Val/Val patients on the one-back task. This randomization analysis relies on across-task and across-group comparisons for one-back condition minus baseline condition in Met/Met patients as opposed to oneback condition minus baseline condition in Val/Val

Molecular Psychiatry

patients. We used an uncorrected alpha of 0.005 in the PET randomization analysis.

Results Genotype frequency distribution of the sample, and working memory/executive functioning and MRI frontal lobe volumes broken down by COMT genotype, are summarized in Table 2. Met allele frequency was 0.52 for the whole sample. Genotype distributions did not deviate from Hardy–Weinberg expectations (w2 ¼ 0.50 and 0.95 in healthy volunteer and patient groups respectively, df ¼ 2, P’sZ0.62). Although a greater proportion of schizophrenia patients had the Val/Val genotype (19.5 vs 14.2% in controls), the genotype frequency distributions were not significantly different between the two samples (w2 ¼ 2.56, P ¼ 0.28). There were no significant genotype or genotype-by-group effects on age, educational attainment or full scale IQ (F’sr1.27, df ¼ 2,243, P’sZ0.27). Effects of COMT genotype on working memory/ executive functions The effects of COMT genotype on WCST, digit span backwards and Trail Making tests were examined using ANCOVA analyses. Patients had significantly lower WCST perseverative errors t-scores than healthy volunteers (mean ¼ 52.3 (SD ¼ 13.56) vs 56.6 (SD ¼ 11.10); main effect of group F ¼ 5.14, df ¼ 1,243, P ¼ 0.02). There were no significant genotype or genotype-by-group effects on WCST performance (Table 2 and Figure 1; F’s ¼ 1.74 and 0.32, respectively, df ¼ 2,243, P’sZ0.18). Similarly, patients performed more poorly on digit span (mean’s ¼ 5.98 (SD ¼ 1.77) vs 8.12 (SD ¼ 2.20) in healthy volunteers) and on Trail Making test (mean’s ¼ 49.2 (SD ¼ 36.06) and 28.7 (SD ¼ 15.03), respectively; main effect of group F’sZ20.8, df ¼ 1,200 or 1,211, P’so0.0001). There were also no significant genotype or genotypeby-group effects on digit span or Trail Making performance (Table 2 and Figure 1; F’sr0.53, df ¼ 2,200 or 2,211, P’sZ0.59). Since the patient group had a significantly greater preponderance of male subjects, fewer years of education and lower full scale IQ than healthy volunteers, these three variables were entered as additional covariates in the general linear models. The results remained unchanged, with no significant genotype or genotype-by-group effects on any of the three measures of working memory/executive functioning. Effects of COMT genotype on MRI frontal lobe morphology In all, 49 of the 84 healthy volunteers and 100 of the 168 patients had MRI frontal lobe volumetric data. The remaining 35 healthy volunteers and 68 patients did not have available MRI scans for a variety of reasons, including inability to undergo scanning procedure because of claustrophobia, poor quality

Table 2 Mean (SD) working memory/executive functioning and frontal lobe MRI volumes (cm3) in controls and schizophrenia patients, and ANOVA analyses (F statistic (P)) on the main effects of diagnostic grouping, genotype and genotype-by-grouping (total brain compartment volume and age as covariates) Controls

Patients

Met/Met

Met/Val

Val/Val

Met/Met

Met/Val

Val/Val

18

54

12

38

90

31

Working memory/executive functionsa WCST 53.3 (10.75) Digit span (backwards) 8.3 (2.03) Trail Making test 28.4 (11.80)

56.7 (11.01) 8.2 (2.79) 28.9 (14.68)

60.8 (11.42) 7.6 (2.15) 28.2 (21.18)

50.7 (14.36) 5.9 (1.88) 54.7 (42.70)

52.5 (13.94) 5.9 (2.03) 45.0 (29.32)

53.7 (11.47) 6.2 (2.08) 52.0 (44.32)

Frontal lobe volumes (cm3) GM 277.9 (14.24) WM 184.9 (14.16) CSF 32.2 (14.32)

268.1 (13.67) 177.5 (16.24) 34.5 (15.53)

257.4 (15.54) 174.1 (15.85) 45.0 (28.07)

279.6 (16.51) 184.3 (15.60) 36.5 (16.31)

266.5 (17.33) 174.4 (16.60) 45.4 (18.06)

270.6 (11.49) 173.8 (13.95) 38.9 (23.43)

N

Diagnosis F (P)

Genotype F (P)

Genotype by Diagnosis F (P)

5.14 (0.02) 30.2 (o0.0001) 20.8 (o0.0001)

1.74 (0.18) 0.12 (0.89) 0.34 (0.71)

0.32 (0.73) 0.53 (0.59) 0.46 (0.63)

1.06 (0.35) 0.58 (0.56) 1.43 (0.24)

2.08 (0.13) 0.08 (0.92) 2.58 (0.08)

1.98 (0.16) 0.20 (0.65) 0.37 (0.55)

a WCST: Wisconsin Card Sorting Test (t-scores). WAIS-R digit span, backwards (number of correct, total raw score). Trail Making test (Trail B minus Trail A (s)).

COMT and frontal lobe functions and morphology in schizophrenia B-C Ho et al

Figure 1 Working memory/executive functions performance in healthy volunteers and in schizophrenia patients broken down by COMT genotype.

scans or scans obtained using noncomparable imaging parameters (either on an older or newer scanning protocol). There were no statistically significant differences between healthy volunteers with and without MR data with regard to gender composition, COMT genotype distribution or age (details of statistical analyses available upon request). Patients with MR data were also not significantly different from those without MR data on a variety of sociodemographic and clinical measures: gender composition, COMT genotype distribution, age and duration of illness or symptom severity (details of statistical analyses available upon request). The mean frontal lobe GM, WM and CSF volumes (adjusted for intracranial volume and age) for 49 healthy volunteers and 100 schizophrenia patients broken down by COMT genotype are summarized in Table 2 and Figure 2. There were no statistically significant effects of genotype on frontal lobe mor-

291

Molecular Psychiatry

COMT and frontal lobe functions and morphology in schizophrenia B-C Ho et al

292

location on two consecutive flashes of the checkerboard. Met/Met allele patients had slightly longer reaction times than Val/Val patients, but this difference was not statistically significant (mean’s ¼ 1382.4 and 1248.5 ms, respectively; t ¼ 0.18, df ¼ 10.2, P ¼ 0.86). Randomization analyses indicated that there were no regions within the DLPFC or within the anterior cingulate where Met/Met patients showed significantly greater rCBF than Val/Val patients. Table 3 and Figure 3 summarize brain regions where schizophrenia patients with Met/Met alleles had significantly lower rCBF than patients with Val/Val alleles. While performing the one-back task, Val/Val patients showed greater activation in the left dorsal lateral prefrontal cortex (Brodmann’s area 47) and in the right mesial frontal lobe (Brodmann’s areas 8 and 9).

Discussion

Figure 2 Mean frontal lobe GM, WM and CSF volumes for healthy volunteers and for schizophrenia patients broken down by COMT genotype.

phology (F’so1.43, df ¼ 2,148, P’s40.24). No significant genotype by group interaction effects on frontal GM or WM (F’so2.08, df ¼ 2,148, P’s40.13). Genotype-by-group interaction effects approached but did not achieve statistical significance for frontal CSF volume (F’s ¼ 2.58, df ¼ 2,148, P ¼ 0.08). Effects of COMT genotype on [15O]H2O rCBF during N-back task performance All seven schizophrenia patients with Met/Met alleles and six patients with Val/Val alleles were able to perform the one-back version of the N-back task. Each subject responded correctly by pressing the button when the asterisk appeared at the same Molecular Psychiatry

In this study, we found that V158M COMT genotype frequencies did not differ significantly between schizophrenia patients and healthy volunteers. We also investigated the effects of COMT genotype on a wide range of frontal lobe-related measures. Working memory/executive function performance (in WCST, digit span backwards and Trail Making tests) and MRI frontal lobe volumes (GM, WM and CSF) were not significantly different between genotype groupings. Patients with Val/Val genotype showed greater activation in the frontal lobes than Met/Met patients while performing the N-back task. Although this difference in rCBF, based on a small subset of the sample, may be taken to mean that subjects with valine allele have prefrontal cortical inefficiency, the overall findings from this study do not support a major role for COMT in increasing susceptibility for schizophrenia, or in mediating frontal lobe structure and functions. V158M COMT functional polymorphism is probably the most widely investigated candidate gene in schizophrenia research. The bulk of the evidence to date suggests that this polymorphism confers, at best, a small increase in susceptibility to the disorder. Most case–control studies, as well as our study, have failed to find a significant association between COMT polymorphism and schizophrenia.52,54,55,59–61,82–88 A handful of case–control studies found that the high enzyme activity valine allele had a modest effect on conferring increased risk for schizophrenia.58,63,89 Conversely, the methionine allele has also been reported to occur more frequently among schizophrenia patients than normal controls.90,91 Family-based studies have had equally mixed results, with some studies finding preferential transmission of the valine allele in schizophrenia patients52,56,57 while others have detected no significant associations.92–94 These conflicting results with regard to the role of V158M COMT polymorphism in schizophrenia susceptibility may relate to inadequate statistical power of individual association studies or to variability in association between different ethnic populations.

COMT and frontal lobe functions and morphology in schizophrenia B-C Ho et al

Table 3 Regions where schizophrenia patients with Met/Met alleles had significantly lower rCBF than patients with Val/Val alleles while performing the one-back task Brain regiona

Right cerebellum Left DLPFC (Brodmann 47) Right cerebellum Left precuneus (Brodmann 30) Right mesial frontal lobe (Brodmann 8) Right mesial frontal lobe (Brodmann 8) Left posterior–inferior lobe cerebellum Right middle temporal gyrus

Talairach coordinates x

y

z

36 39 11 10 5 9 32 47

52 20 61 55 23 53 67 30

36 3 36 19 31 13 40 6

Significance of tmax (P)b

3.58 3.20 3.11 3.28 3.03 3.11 3.21 3.18

(0.0005) (0.0014) (0.0018) (0.0011) (0.0022) (0.0018) (0.0014) (0.0015)

293

Number of voxelsc

1.2 0.4 0.3 0.3 0.2 0.2 0.2 0.1

a Regions were named from the inspection of coregistered magnetic resonance and PET images, as well as Talairach coordinates. These coordinates represent spatial orientation with respect to a point located in a horizontal plane through the anterior and posterior commissures (z ¼ 0), at the midline of the brain slice (x ¼ 0) and at the anterior commissure line (y ¼ 0). The x-axis was the distance in millimeters to the left (negative) and to the right (positive) of the midline. The y-axis was the distance in millimeters anterior (positive) or posterior (negative) to the anterior commissure line. The z-axis was the distance in millimeters above (positive) or below (negative) a horizontal plane through the anterior and posterior commissures. b tmax is the highest t-value identified in the peak. c Number of voxels in the peaks that exceeded alpha ¼ 0.005.

Figure 3 Regions where cerebral blood flow among Met/ Met schizophrenia patients were significantly lower than those in Val/Val patients while performing the one-back task.

When data from case–control association studies were pooled, the two published meta-analyses indicate that V158M COMT allele variation does not contribute to increased vulnerability for schizophrenia.62,95 Familybased studies, on the other hand, suggest that the valine allele may be a risk factor in schizophrenia patients of European ancestry.62 To clarify the true role of the V158M COMT polymorphism in schizo-

phrenia susceptibility, future studies will require larger sample sizes and will need to minimize the effects of population stratification. Beyond its potential as a susceptibility gene, there has also been a long-standing interest within schizophrenia research with regard to the phenotypic correlates of the COMT gene. The methionine allele has been associated with aggression, suicide, worse prognosis and greater positive symptom severity in schizophrenia.91,96–100 Egan et al’s finding of an association between the valine allele and poor WCST performance has generated renewed interest in this area of investigation, especially with regard to the effects of COMT in mediating cognition in schizophrenia.52 This finding has been replicated in part by Joober et al, who found that genotype effects on WCST performance among schizophrenia patients was at a trend level of significance, and was nonsignificant in healthy volunteers.59 In another study, healthy volunteers with the valine allele committed significantly more WCST perseverative errors than those with methionine allele.101 The effects of V158M COMT polymorphism appear to extend beyond WCST performance, and have been implicated in other measures of prefrontal neurocognitive functions (such as N-back task102 and prefrontal P300 amplitude and latency103,104), and in mediating other cognitive domains (such as processing speed and attention105 and ‘cognitive stability and flexibility’106). All these studies have found an association between the valine allele and poorer cognitive performance, and postulate that the underlying mechanism may be related to lower prefrontal dopamine levels arising from higher dopamine catabolism mediated by the valine allele. Molecular Psychiatry

COMT and frontal lobe functions and morphology in schizophrenia B-C Ho et al

294

In contrast to these previous studies, we did not find a significant association between the high enzyme activity valine allele and poor WCST performance. In fact, among schizophrenia patients as well as healthy volunteers, none of the working memory/ executive function measures we examined differed significantly across genotype groupings. Our findings of no significant genotype effects are consistent with a recent study involving 200 healthy volunteers.107 Fossella et al found that V158M COMT genotype status did not predict performance in any of the four measures of attention they examined. Interestingly, healthy volunteers with alleles expected to result in higher synaptic dopamine actually performed more poorly in the attention tasks. The four-repeat allele of the DRD4 exon III polymorphism and 10-repeat allele of the DAT 30 -VNTR polymorphism were both significantly associated with poorer executive attention scores. Although the COMT Met allele showed no significant associations, subjects with Met/Met genotype had numerically worse attention scores. The MAOA-LPR three-repeat allele, which would also be expected to result in higher synaptic dopamine levels, showed a trend towards poorer attention performance. The younger age, milder cognitive impairment and/ or shorter illness duration of our sample may potentially explain our nonreplication of the association between the valine allele and poor cognitive performance. Except for the Tsai et al study104 (which studied Han Chinese female nursing students aged between 19 and 21 years), the mean age of subjects in previous studies52,59,101–103,105,106,108 are substantially older than ours. Age-related loss in frontal lobe dopamine function has been repeatedly demonstrated in post-mortem as well as in vivo neuroimaging studies (eg Rinne,109 de Keyser et al,110 Suhara et al,111 Kaasinen et al112 and Volkow et al113). This decline in dopamine function appears to begin early,114 and has been estimated to occur at a rate of 11–13% per decade in age.112 Thus, even though subjects from previous studies52,59,101–103,105,106,108 were still in their mid-adulthood, and were only 10–15 years older than our sample, these older subjects may already have considerably lower dopamine functional reserve than our younger subjects. Any further reduction in dopamine function among these older individuals, such as an increased dopamine catabolism associated with the presence of valine allele, may have more pronounced detrimental effects on frontal lobe functions than in younger individuals. Compared with the Egan et al and Bilder et al studies,52,105 which examined similar neuropsychological measures, our sample was cognitively less impaired and our patients less chronically ill. The mean WCST t-scores for patients and controls in Egan et al study were 37.6 (712.6) and 49.4 (79.0), respectively52 (vs 52.3 (712.2) and 56.6 (79.6) in our patients and controls subjects, respectively). In the Bilder et al study,105 the mean number of perseverative errors among schizophrenia patients

Molecular Psychiatry

was 49.2 (vs 11.2 in our patients). The mean illness duration among patients in the Bilder et al study and in our study is 19.3 and 2.5 years, respectively. Although the Egan et al study did not report illness duration, the average length of illness would likely be 10–12 years based on the mean age of the subjects. These differences in severity of cognitive impairment and in duration of illness may be indicative of greater heterogeneity in our patient sample. Even though all three studies utilized DSM diagnostic criteria to ascertain patients, it is well recognized that there can be substantial variability in patients who share the same set of clinical symptoms of schizophrenia. Since our patients consisted of a mixture of first episode, recent-onset and chronically ill schizophrenia patients, our sample may be more representative of the ‘average’ schizophrenia patient. However, this heterogeneity will likely add ‘noise’ to the analyses, and may be less ideal for genetic association studies. On the other hand, the Egan et al and Bilder et al samples, being more chronically ill and having greater cognitive impairment, may be genetically more homogeneous, and therefore, more likely to detect effects of COMT genotype on cognitive performance. A third reason for our lack of significant associations between COMT genotype and working memory performance may be related to the secondary role of COMT in determining synaptic dopamine levels. There is limited human data with regard to the relative contributions of catecholamine (dopamine and norepinephrine) transporters, monoamine oxidase and COMT in influencing synaptic dopamine levels in the prefrontal cortex. However, animal studies indicate that COMT plays only a minimal role in the clearance of synaptic dopamine, even under conditions of low dopamine transporter activity.45–47 Furthermore, COMT genotype appears to account for only a small amount (2–4%) of shared variance with WCST performance.52,105 Thus, this small effect of COMT genotype on cognitive performance may be especially difficult to detect in younger and more heterogeneous sample of schizophrenia patients. To the best of our knowledge, this is the first study that has examined MRI brain morphometric correlates of COMT genotype. We did not find any significant associations between genotype and frontal GM, WM or CSF volumes. Although our group has previously reported associations between BDNF and NOTCH4 with these same measures of frontal lobe,115,116 future studies on the relationships between COMT and brain morphology will need to examine specific regions within the frontal lobes, especially regions known to mediate working memory. Our finding of Val/Val patients having greater frontal lobe activation than Met/Met patients while performing the one-back working memory task is consistent with Egan et al study.52 The authors found greater fMRI BOLD response in the DLPFC and anterior cingulate among unaffected siblings of

COMT and frontal lobe functions and morphology in schizophrenia B-C Ho et al

schizophrenia patients with Val/Val genotype. Since our Val/Val patients had comparable reaction times as our Met/Met patients and the one-back task is a low load working memory test, higher frontal lobe rCBF among our Val/Val patients suggests that they may be ‘working harder’ in order to achieve equal task performance. While relative prefrontal cortical inefficiency in the valine allele may be a plausible interpretation of these PET study findings, a diametrically opposite view could be that lower frontal lobe rCBF among Met/Met patients may represent hypofrontality relative to Val/Val patients. Both hypofrontality as well as hyperfrontality have been described in schizophrenia. Unfortunately, we did not have sufficient numbers of healthy volunteers with Met/ Met and Val/Val genotypes to assess the patients’ relative brain activations. As Manoach117 has elegantly presented, the interpretation of functional neuroimaging findings in schizophrenia is complex, and a variety of reasons (ranging from methodological issues to heterogeneity of schizophrenia) may account for the seemingly discrepant findings of both hypofrontality as well as increased prefrontal activity in schizophrenia. Irrespective of how these PET findings may be interpreted, that Val/Val patients and Met/Met patients differed significantly on frontal lobe rCBF seem inconsistent with the rest of our findings of no significant COMT genotype effects on a variety of frontal lobe-related measures. Cerebral blood flow, being a more direct measure of neuronal function, may be more sensitive for assessing the effects of COMT genotype than are neuropsychological measures or MRI brain morphometry. Conversely, our PET study involved only 13 patients, and the larger sample size used in the rest of this study may provide results that can be better generalized to the average patient with schizophrenia. Future efforts to integrate functional neuroimaging toward better understanding the effects of COMT genotype on cognitive endophenotypes of schizophrenia will require large samples of both patients as well as healthy volunteers. Working memory load will also need to be varied in future functional neuroimaging studies so as to be better able to interpret differences in brain activation between COMT genotypes.

Conclusion The complex genetics and phenotypic heterogeneity remain as major obstacles in schizophrenia research. Integrating multimodal investigational approaches will help address these challenges, and facilitate greater understanding of the neurobiological basis for this group of disorders.

Acknowledgements This research was supported in part by NIMH Grants MH31593, MH40856 and MH43271. Parts of this research were presented at the IXth International

Congress on Schizophrenia Research, Springs, CO, March 28–April 2, 2003.

Colorado

295

References 1 Andreasen NC. Schizophrenia: the fundamental questions. Brain Res Brain Res Rev 2000; 31: 106–112. 2 Kennedy JL, Farrer LA, Andreasen NC, Mayeux R, St GeorgeHyslop P. The genetics of adult-onset neuropsychiatric disease: complexities and conundra? Science 2003; 302: 822–826. 3 Moldin SO. Indicators of liability to schizophrenia: perspectives from genetic epidemiology. Schizophr Bull 1994; 20: 169–184. 4 Thaker GK. Current progress in schizophrenia research. Search for genes of schizophrenia: back to defining valid phenes. J Nerv Ment Dis 2002; 190: 411–412. 5 Almasy L, Blangero J. Endophenotypes as quantitative risk factors for psychiatric disease: rationale and study design. Am J Med Genet 2001; 105: 42–44. 6 Tsuang MT, Faraone SV. The frustrating search for schizophrenia genes. Am J Med Genet (Semin Med Genet) 2000; 97: 1–3. 7 Gottesman II, Gould TD. The endophenotype concept in psychiatry: etymology and strategic intentions. Am J Psychiatry 2003; 160: 636–645. 8 Arolt V, Lencer R, Nolte A, Muller-Myhsok B, Purmann S, Schurmann M et al. Eye tracking dysfunction is a putative phenotypic susceptibility marker of schizophrenia and maps to a locus on chromosome 6p in families with multiple occurrence of the disease. Am J Med Genet 1996; 67: 564–579. 9 Freedman R, Coon H, Myles-Worsley M, Orr-Urtreger A, Olincy A, Davis A et al. Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus. Proc Natl Acad Sci USA 1997; 94: 587–592. 10 Liu H, Heath SC, Sobin C, Roos JL, Galke BL, Blundell ML et al. Genetic variation at the 22q11 PRODH2/DGCR6 locus presents an unusual pattern and increases susceptibility to schizophrenia. Proc Natl Acad Sci USA 2002; 99: 3717–3722. 11 Leal SM. Phenotypes and genetic analysis of psychiatric and neuropsychiatric traits. Am J Med Genet 2001; 105: 4–7. 12 Baddeley A. Working memory. Science 1992; 255: 556–559. 13 Cohen JD, Braver TS, O’Reilly RC. A computational approach to prefrontal cortex, cognitive control and schizophrenia: recent developments and current challenges. Philos Trans R Soc Lond Ser B 1996; 351: 1515–1527. 14 Goldman-Rakic PS. Prefrontal cortical dysfunction in schizophrenia: the relevance of working memory. In: Carroll BJ, Barrett JE (eds). Psychopathology and the Brain. Raven Press: New York, NY, 1990 pp 1–23. 15 Park S, Holzman PS. Schizophrenics show spatial working memory deficits. Arch Gen Psychiatry 1992; 49: 975–982. 16 Park S, Holzman PS, Goldman-Rakic PS. Spatial working memory deficits in the relatives of schizophrenic patients. Arch Gen Psychiatry 1995; 52: 821–828. 17 Goldberg TE, Torrey EF, Gold JM, Ragland JD, Bigelow LB, Weinberger DR. Learning and memory in monozygotic twins discordant for schizophrenia. Psychol Med 1993; 23: 71–85. 18 Cannon TD, Bearden CE, Hollister JM, Rosso IM, Sanchez LE, Hadley T. Childhood cognitive functioning in schizophrenia patients and their unaffected siblings: a prospective cohort study. Schizophr Bull 2000; 26: 379–393. 19 Myles-Worsley M, Park S. Spatial working memory deficits in schizophrenia patients and their first degree relatives from Palau, Micronesia. Am J Med Genet 2002; 114: 609–615. 20 Tuulio-Henriksson A, Arajarvi R, Partonen T, Haukka J, Varilo T, Schreck M et al. Familial loading associates with impairment in visual span among healthy siblings of schizophrenia patients. Biol Psychiatry 2003; 54: 623–628. 21 Tuulio-Henriksson A, Haukka J, Partonen T, Varilo T, Paunio T, Ekelund J et al. Heritability and number of quantitative trait loci of neurocognitive functions in families with schizophrenia. Am J Med Genet 2002; 114: 483–490. 22 Conklin HM, Curtis CE, Katsanis J, Iacono WG. Verbal working memory impairment in schizophrenia patients and their Molecular Psychiatry

COMT and frontal lobe functions and morphology in schizophrenia B-C Ho et al

296 23

24 25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

first-degree relatives: evidence from the digit span task. Am J Psychiatry 2000; 157: 275–277. Farmer CM, O’Donnell BF, Niznikiewicz MA, Voglmaier MM, McCarley RW, Shenton ME. Visual perception and working memory in schizotypal personality disorder. Am J Psychiatry 2000; 157: 781–788. Ando J, Ono Y, Wright MJ. Genetic structure of spatial and verbal working memory. Behav Genet 2001; 31: 615–624. Cannon TD, Huttunen MO, Lonnqvist J, Tuulio-Henriksson A, Pirkola T, Glahn D et al. The inheritance of neuropsychological dysfunction in twins discordant for schizophrenia. Am J Hum Genet 2000; 67: 369–382. Gold S, Arndt S, Nopoulos P, O’Leary DS, Andreasen NC. Longitudinal study of cognitive function in first-episode and recent-onset schizophrenia. Am J Psychiatry 1999; 156: 1342–1348. Goldberg TE, Weinberger DR. Effects of neuroleptic medications on the cognition of patients with schizophrenia: a review of recent studies. J Clin Psychiatry 1996; 57: 62–65. Carter C, Robertson L, Nordahl T, Chaderjian M, Kraft L, O’ShoraCelaya L. Spatial working memory deficits and their relationship to negative symptoms in unmedicated schizophrenia patients. Biol Psychiatry 1996; 40: 930–932. Barch DM, Carter CS, Braver TS, Sabb FW, MacDonald III A, Noll DC et al. Selective deficits in prefrontal cortex function in medication-naive patients with schizophrenia. Arch Gen Psychiatry 2001; 58: 280–288. Keefe RS, Silva SG, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull 1999; 25: 201–222. Friedman HR, Goldman-Rakic PS. Coactivation of prefrontal cortex and inferior parietal cortex in working memory tasks revealed by 2DG functional mapping in the rhesus monkey. J Neurosci 1994; 14(Part 1): 2775–2788. Petrides M, Alivisatos B, Meyer E, Evans AC. Functional activation of the human frontal cortex during the performance of verbal working memory tasks. Proc Natl Acad Sci USA 1993; 90: 878–882. Lewis DA, Campbell MJ, Foote SL, Goldstein M, Morrison JH. The distribution of tyrosine hydroxylase-immunoreactive fibers in primate neocortex is widespread but regionally specific. J Neurosci 1987; 7: 279–290. Levitt P, Rakic P, Goldman-Rakic P. Region-specific distribution of catecholamine afferents in primate cerebral cortex: a fluorescence histochemical analysis. J Comp Neurol 1984; 227: 23–36. Lidow MS, Goldman-Rakic PS, Gallager DW, Rakic P. Distribution of dopaminergic receptors in the primate cerebral cortex: quantitative autoradiographic analysis using [3H]raclopride, [3H]spiperone and [3H]SCH23390. Neuroscience 1991; 40: 657–671. Hurd YL, Suzuki M, Sedvall GC. D1 and D2 dopamine receptor mRNA expression in whole hemisphere sections of the human brain. J Chem Neuroanat 2001; 22: 127–137. Brozoski TJ, Brown RM, Rosvold HE, Goldman PS. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979; 205: 929–932. Sawaguchi T, Goldman-Rakic PS. The role of D1-dopamine receptor in working memory: local injections of dopamine antagonists into the prefrontal cortex of rhesus monkeys performing an oculomotor delayed-response task. J Neurophysiol 1994; 71: 515–528. Callicott JH, Bertolino A, Mattay VS, Langheim FJ, Duyn J, Coppola R et al. Physiological dysfunction of the dorsolateral prefrontal cortex in schizophrenia revisited. Cereb Cortex 2000; 10: 1078–1092. Stevens AA, Goldman-Rakic PS, Gore JC, Fulbright RK, Wexler BE. Cortical dysfunction in schizophrenia during auditory word and tone working memory demonstrated by functional magnetic resonance imaging. Arch Gen Psychiatry 1998; 55: 1097–1103. Honey GD, Bullmore ET, Soni W, Varatheesan M, Williams SC, Sharma T. Differences in frontal cortical activation by a working memory task after substitution of risperidone for typical

Molecular Psychiatry

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

antipsychotic drugs in patients with schizophrenia. Proc Natl Acad Sci USA 1999; 96: 13432–13437. Manoach DS, Press DZ, Thangaraj V, Searl MM, Goff DC, Halpern E et al. Schizophrenic subjects activate dorsolateral prefrontal cortex during a working memory task, as measured by fMRI. Biol Psychiatry 1999; 45: 1128–1137. Manoach DS, Gollub RL, Benson ES, Searl MM, Goff DC, Halpern E et al. Schizophrenic subjects show aberrant fMRI activation of dorsolateral prefrontal cortex and basal ganglia during working memory performance. Biol Psychiatry 2000; 48: 99–109. Karoum F, Chrapusta SJ, Egan MF. 3-Methoxytyramine is the major metabolite of released dopamine in the rat frontal cortex: reassessment of the effects of antipsychotics on the dynamics of dopamine release and metabolism in the frontal cortex, nucleus accumbens, and striatum by a simple two pool model. J Neurochem 1994; 63: 972–979. Huotari M, Gogos JA, Karayiorgou M, Koponen O, Forsberg M, Raasmaja A et al. Brain catecholamine metabolism in catechol-Omethyltransferase (COMT)-deficient mice. Eur J Neurosci 2002; 15: 246–256. Wayment HK, Schenk JO, Sorg BA. Characterization of extracellular dopamine clearance in the medial prefrontal cortex: role of monoamine uptake and monoamine oxidase inhibition. J Neurosci 2001; 21: 35–44. Moron JA, Brockington A, Wise RA, Rocha BA, Hope BT. Dopamine uptake through the norepinephrine transporter in brain regions with low levels of the dopamine transporter: evidence from knock-out mouse lines. J Neurosci 2002; 22: 389–395. Palmatier MA, Kang AM, Kidd KK. Global variation in the frequencies of functionally different catechol-O-methyltransferase alleles. Biol Psychiatry 1999; 46: 557–567. Lotta T, Vidgren J, Tilgmann C, Ulmanen I, Melen K, Julkunen I et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34: 4202–4210. Badner JA, Gershon ES. Meta-analysis of whole-genome linkage scans of bipolar disorder and schizophrenia. Mol Psychiatry 2002; 7: 405–411. Murphy KC, Jones LA, Owen MJ. High rates of schizophrenia in adults with velo-cardio-facial syndrome. Arch Gen Psychiatry 1999; 56: 940–945. Egan MF, Goldberg TE, Kolachana BS, Callicott JH, Mazzanti CM, Straub RE et al. Effect of COMT Val108/158 Met genotype on frontal lobe function and risk for schizophrenia. Proc Natl Acad Sci USA 2001; 98: 6917–6922. Weinberger DR, Egan MF, Bertolino A, Callicott JH, Mattay VS, Lipska BK et al. Prefrontal neurons and the genetics of schizophrenia. Biol Psychiatry 2001; 50: 825–844. Daniels JK, Williams NM, Williams J, Jones LA, Cardno AG, Murphy KC et al. No evidence for allelic association between schizophrenia and a polymorphism determining high or low catechol O-methyltransferase activity. Am J Psychiatry 1996; 153: 268–270. Karayiorgou M, Gogos JA, Galke BL, Wolyniec PS, Nestadt G, Antonarakis SE et al. Identification of sequence variants and analysis of the role of the catechol-O-methyl-transferase gene in schizophrenia susceptibility. Biol Psychiatry 1998; 43: 425–431. Li T, Sham PC, Vallada H, Xie T, Tang X, Murray RM et al. Preferential transmission of the high activity allele of COMT in schizophrenia. Psychiatr Genet 1996; 6: 131–133. Kunugi H, Vallada HP, Sham PC, Hoda F, Arranz MJ, Li T et al. Catechol-O-methyltransferase polymorphisms and schizophrenia: a transmission disequilibrium study in multiplying affected families. Psychiatr Genet 1997; 7: 97–101. de Chaldee M, Laurent C, Thibaut F, Martinez M, Samolyk D, Petit M et al. Linkage disequilibrium on the COMT gene in French schizophrenics and controls. Am J Med Genet 1999; 88: 452–457. Joober R, Gauthier J, Lal S, Bloom D, Lalonde P, Rouleau G et al. Catechol-O-methyltransferase Val-108/158-Met gene variants associated with performance on the Wisconsin Card Sorting Test. Arch Gen Psychiatry 2002; 59: 662–663.

COMT and frontal lobe functions and morphology in schizophrenia B-C Ho et al 60 Park TW, Yoon KS, Kim JH, Park WY, Hirvonen A, Kang D. Functional catechol-O-methyltransferase gene polymorphism and susceptibility to schizophrenia. Eur Neuropsychopharmacol 2002; 12: 299–303. 61 Norton N, Kirov G, Zammit S, Jones G, Jones S, Owen R et al. Schizophrenia and functional polymorphisms in the MAOA and COMT genes: no evidence for association or epistasis. Am J Med Genet 2002; 114: 491–496. 62 Glatt SJ, Faraone SV, Tsuang MT. Association between a functional catechol O-methyltransferase gene polymorphism and schizophrenia: meta-analysis of case–control and familybased studies. Am J Psychiatry 2003; 160: 469–476. 63 Wonodi I, Stine OC, Mitchell BD, Buchanan RW, Thaker GK. Association between Val108/158 Met polymorphism of the COMT gene and schizophrenia. Am J Med Genet 2003; 120B: 47–50. 64 Andreasen NC, Flaum M, Arndt S. The Comprehensive Assessment of Symptoms and History (CASH). An instrument for assessing diagnosis and psychopathology. Arch Gen Psychiatry 1992; 49: 615–623. 65 Lahiri DK, Nurnberger Jr JI. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 1991; 19: 5444. 66 Perry W, Heaton RK, Potterat E, Roebuck T, Minassian A, Braff DL. Working memory in schizophrenia: transient ‘online’ storage versus executive functioning. Schizophr Bull 2001; 27: 157–176. 67 Pukrop R, Matuschek E, Ruhrmann S, Brockhaus-Dumke A, Tendolkar I, Bertsch A et al. Dimensions of working memory dysfunction in schizophrenia. Schizophr Res 2003; 62: 259–268. 68 Heaton RK, Chelune GK, Talley JL, Kay GG, Curtiss G. Wisconsin Card Sorting Test Manual. Psychological Assessment Resources Inc.: Odessa, FL, 1993. 69 Reitan RM. Validity of the Trail Making Test as an indicator of organic brain damage. Percept Motor Skills 1958; 8: 271–276. 70 Jarvis PE, Barth JT. Halstead-Reitan Test Battery: An Interpretative Guide. Psychological Assessment Resources: Odessa, FL, 1986. 71 Andreasen NC, Cohen G, Harris G, Cizadlo T, Parkkinen J, Rezai K et al. Image processing for the study of brain structure and function: problems and programs. J Neuropsychiatry Clin Neurosci 1992; 4: 125–133. 72 Andreasen NC, Cizadlo T, Harris G, Swayze V, O’Leary DS, Cohen G et al. Voxel processing techniques for the antemortem study of neuroanatomy and neuropathology using magnetic resonance imaging. J Neuropsychiatry Clin Neurosci 1993; 5: 121–130. 73 Andreasen NC, Harris G, Cizadlo T, Arndt S, O’Leary DS, Swayze V et al. Techniques for measuring sulcal/gyral patterns in the brain as visualized through magnetic resonance scanning: BRAINPLOT and BRAINMAP. Proc Natl Acad Sci USA 1994; 91: 93–97. 74 Magnotta VA, Heckel D, Andreasen NC, Cizadlo T, Corson PW, Ehrhardt JC et al. Measurement of brain structures with artificial neural networks: two- and three-dimensional applications. Radiology 1999; 211: 781–790. 75 Woods RP, Cherry SR, Mazziotta JC. Rapid automated algorithm for aligning and reslicing PET images. J Comput Assist Tomogr 1992; 16: 620–633. 76 Talairach J, Tournoux P. Co-Planar Stereotaxic Atlas of the Human Brain. Thieme Medical Publishers: New York, 1988. 77 Andreasen NC, Rajarethinam R, Cizadlo T, Arndt S, Swayze II VW, Flashman LA et al. Automatic atlas-based volume estimation of human brain regions from MR images. J Comput Assist Tomogr 1996; 20: 98–106. 78 Harris G, Andreasen NC, Cizadlo T, Bailey JM, Bockholt HJ, Magnotta VA et al. Improving tissue classification in MRI: a three-dimensional multispectral discriminant analysis method with automated training class selection. J Comput Assist Tomogr 1999; 23: 144–154. 79 Herscovitch P, Markham J, Raichle ME. Brain blood flow measured with intravenous H2(15)O. I. Theory and error analysis. J Nucl Med 1983; 24: 782–789. 80 Hichwa RD, Boles Ponto LL, Watkins GL. Clinical blood flow measurement with [15O]water and positron emission tomography

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

(PET). In: Emran AM (ed). Chemists’ Views of Imaging Centers. Plenum Press: New York, 1995 pp 401–417. Arndt S, Cizadlo T, Andreasen NC, Heckel D, Gold S, O’Leary DS. Tests for comparing images based on randomization and permutation methods. J Cereb Blood Flow Metab 1996; 16: 1271–1279. Strous RD, Bark N, Woerner M, Lachman HM. Lack of association of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia. Biol Psychiatry 1997; 41: 493–495. Chen CH, Lee YR, Wei FC, Koong FJ, Hwu HG, Hsiao KJ. Association study of NlaIII and MspI genetic polymorphisms of catechol-O-methyltransferase gene and susceptibility to schizophrenia. Biol Psychiatry 1997; 41: 985–987. Chen CH, Lee YR, Chung MY, Wei FC, Koong FJ, Shaw CK et al. Systematic mutation analysis of the catechol O-methyltransferase gene as a candidate gene for schizophrenia. Am J Psychiatry 1999; 156: 1273–1275. Arinami T, Ohtsuki T, Takase K, Shimizu H, Yoshikawa T, Horigome H et al. Screening for 22q11 deletions in a schizophrenia population. Schizophr Res 2001; 52: 167–170. Herken H, Erdal ME. Catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association between symptomatology and prognosis. Psychiatr Genet 2001; 11: 105–109. Liou YJ, Tsai SJ, Hong CJ, Wang YC, Lai IC. Association analysis of a functional catechol-o-methyltransferase gene polymorphism in schizophrenic patients in Taiwan. Neuropsychobiology 2001; 43: 11–14. Inada T, Nakamura A, Iijima Y. Relationship between catechol-Omethyltransferase polymorphism and treatment-resistant schizophrenia. Am J Med Genet 2003; 120B: 35–39. Shifman S, Bronstein M, Sternfeld M, Pisante-Shalom A, LevLehman E, Weizman A et al. A highly significant association between a COMT haplotype and schizophrenia. Am J Hum Genet 2002; 71: 1296–1302. Ohmori O, Shinkai T, Kojima H, Terao T, Suzuki T, Mita T et al. Association study of a functional catechol-O-methyltransferase gene polymorphism in Japanese schizophrenics. Neurosci Lett 1998; 243: 109–112. Kotler M, Barak P, Cohen H, Averbuch IE, Grinshpoon A, Gritsenko I et al. Homicidal behavior in schizophrenia associated with a genetic polymorphism determining low catechol Omethyltransferase (COMT) activity. Am J Med Genet 1999; 88: 628–633. Wei J, Hemmings GP. Lack of evidence for association between the COMT locus and schizophrenia. Psychiatr Genet 1999; 9: 183–186. de Chaldee M, Corbex M, Campion D, Jay M, Samolyk D, Petit M et al. No evidence for linkage between COMT and schizophrenia in a French population. Psychiatry Res 2001; 102: 87–90. Semwal P, Prasad S, Bhatia T, Deshpande SN, Wood J, Nimgaonkar VL et al. Family-based association studies of monoaminergic gene polymorphisms among North Indians with schizophrenia. Mol Psychiatry 2001; 6: 220–224. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN. Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet 2003; 33: 177–182. Strous RD, Bark N, Parsia SS, Volavka J, Lachman HM. Analysis of a functional catechol-O-methyltransferase gene polymorphism in schizophrenia: evidence for association with aggressive and antisocial behavior. Psychiatry Res 1997; 69: 71–77. Lachman HM, Nolan KA, Mohr P, Saito T, Volavka J. Association between catechol O-methyltransferase genotype and violence in schizophrenia and schizoaffective disorder. Am J Psychiatry 1998; 155: 835–837. Nolan KA, Volavka J, Czobor P, Cseh A, Lachman H, Saito T et al. Suicidal behavior in patients with schizophrenia is related to COMT polymorphism. Psychiatr Genet 2000; 10: 117–124. Jones G, Zammit S, Norton N, Hamshere ML, Jones SJ, Milham C et al. Aggressive behaviour in patients with schizophrenia is associated with catechol-O-methyltransferase genotype. Br J Psychiatry 2001; 179: 351–355.

297

Molecular Psychiatry

COMT and frontal lobe functions and morphology in schizophrenia B-C Ho et al

298

100 Illi A, Kampman O, Anttila S, Roivas M, Mattila KM, Lehtimaki T et al. Interaction between angiotensin-converting enzyme and catechol-O-methyltransferase genotypes in schizophrenics with poor response to conventional neuroleptics. Eur Neuropsychopharmacol 2003; 13: 147–151. 101 Malhotra AK, Kestler LJ, Mazzanti C, Bates JA, Goldberg T, Goldman D. A functional polymorphism in the COMT gene and performance on a test of prefrontal cognition. Am J Psychiatry 2002; 159: 652–654. 102 Goldberg TE, Egan MF, Gscheidle T, Coppola R, Weickert T, Kolachana BS et al. Executive subprocesses in working memory: relationship to catechol-O-methyltransferase Val158Met genotype and schizophrenia. Arch Gen Psychiatry 2003; 60: 889–896. 103 Gallinat J, Bajbouj M, Sander T, Schlattmann P, Xu K, Ferro EF et al. Association of the G1947A COMT (Val(108/158)Met) gene polymorphism with prefrontal P300 during information processing. Biol Psychiatry 2003; 54: 40–48. 104 Tsai SJ, Yu YW, Chen TJ, Chen JY, Liou YJ, Chen MC et al. Association study of a functional catechol-O-methyltransferasegene polymorphism and cognitive function in healthy females. Neurosci Lett 2003; 338: 123–126. 105 Bilder RM, Volavka J, Czobor P, Malhotra AK, Kennedy JL, Ni X et al. Neurocognitive correlates of the COMT Val(158)Met polymorphism in chronic schizophrenia. Biol Psychiatry 2002; 52: 701–707. 106 Nolan KA, Bilder RM, Lachman HM, Volavka J. Catechol Omethyltransferase Val158Met polymorphism in schizophrenia: differential effects of Val and Met alleles on cognitive stability and flexibility. Am J Psychiatry 2004; 161: 359–361. 107 Fossella J, Sommer T, Fan J, Wu Y, Swanson JM, Pfaff DW et al. Assessing the molecular genetics of attention networks. BMC Neurosci 2002; 3: 14.

Molecular Psychiatry

108 Joober R, Rouleau GA, Lal S, Dixon M, O’Driscoll G, Palmour R et al. Neuropsychological impairments in neuroleptic-responder vs nonresponder schizophrenic patients and healthy volunteers. Schizophr Res 2002; 53: 229–238. 109 Rinne JO. Muscarinic and dopaminergic receptors in the aging human brain. Brain Res 1987; 404: 162–168. 110 de Keyser J, De Backer JP, Vauquelin G, Ebinger G. The effect of aging on the D1 dopamine receptors in human frontal cortex. Brain Res 1990; 528: 308–310. 111 Suhara T, Fukuda H, Inoue O, Itoh T, Suzuki K, Yamasaki T et al. Age-related changes in human D1 dopamine receptors measured by positron emission tomography. Psychopharmacology (Berl) 1991; 103: 41–45. 112 Kaasinen V, Vilkman H, Hietala J, Nagren K, Helenius H, Olsson H et al. Age-related dopamine D2/D3 receptor loss in extrastriatal regions of the human brain. Neuobiol Aging 2000; 21: 683–688. 113 Volkow ND, Logan J, Fowler JS, Wang GJ, Gur RC, Wong C et al. Association between age-related decline in brain dopamine activity and impairment in frontal and cingulate metabolism. Am J Psychiatry 2000; 157: 75–80. 114 Goldman-Rakic PS, Brown RM. Regional changes of monoamines in cerebral cortex and subcortical structures of aging rhesus monkeys. Neuroscience 1981; 6: 177–187. 115 Wassink TH, Crowe RR, Andreasen NC. Tumor necrosis factor receptor—II: heritability and effect on brain morphology in schizophrenia. Mol Psychiatry 2000; 5: 678–682. 116 Wassink TH, Nopoulos P, Pietila J, Crowe RR, Andreasen NC. NOTCH4 and the frontal lobe in schizophrenia. Am J Med Genet 2003; 118B: 1–7. 117 Manoach DS. Prefrontal cortex dysfunction during working memory performance in schizophrenia: reconciling discrepant findings. Schizophr Res 2003; 60: 285–298.